George X. Wang

发表

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

C. Divino, J. Kao, M. Meseck, 2009, Cancer research.

Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity

J. Haidar, M. Kalos, S. Eastman, 2020, Cancer Immunology Research.

Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function.

C. Divino, Shu-Hsia Chen, Bingjiao Yin, 2008, Blood.

Development of a 2-Plex Luminex-Based Competitive Immunoassay to Quantify Neutralizing Antibodies Induced by Virus-Like Particles for Human Papillomavirus 16 and 18

Hongfang Wang, George X. Wang, Hongmei Zhu, 2011, Journal of biomedicine & biotechnology.

factor function myeloid-derived suppressor cell development by blockade of stem-cell Reversion of immune tolerance in advanced malignancy: modulation of

C. Divino, Bingjiao Yin, George X. Wang, 2013 .

Reversion of immune tolerance in advanced malignancy : modulation of myeloid derived suppressor cell development by blockade of SCF function

C. Divino, Shu-Hsia Chen, Bingjiao Yin, 2007 .

Myeloid-Derived Suppressor Cells Prevent Type 1 Diabetes in Murine Models

C. Divino, Ge Ma, Shu-Hsia Chen, 2010, The Journal of Immunology.

Type 1 Diabetes in Murine Models Myeloid-Derived Suppressor Cells Prevent

C. Divino, Ge Ma, Shu-Hsia Chen, 2010 .

A Functional Recombinant Human 4-1BB Ligand for Immune Costimulatory Therapy of Cancer

M. Meseck, S. Woo, Ge Ma, 2011, Journal of immunotherapy.

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

J. Haidar, M. Kalos, Leyi Shen, 2018, Journal of Immunotherapy for Cancer.

Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.

C. Divino, Ge Ma, Shu-Hsia Chen, 2010, Cancer research.

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

J. Haidar, M. Kalos, Leyi Shen, 2018, Journal of Immunotherapy for Cancer.

Development and Analytical Validation of a BT-474 Anti-Proliferation Assay Targeting HER2

Hongfang Wang, George X. Wang, P. Lv, 2012 .

Engineered Cell Line Imaging Assay Differentiates Pathogenic from Non-Pathogenic Bacteria

Z. Stromberg, B. M. Hess, George X. Wang, 2022, Pathogens.

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

C. Divino, J. Kao, M. Meseck, 2009, Cancer research.